Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk.

IF 5.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Current Diabetes Reports Pub Date : 2024-07-01 Epub Date: 2024-05-28 DOI:10.1007/s11892-024-01543-5

Corral Pablo, Arrupe Matías, Augusto Lavalle Cobo, Gimenez Sergio, Renna Nicolás Federico

{"title":"Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk.","authors":"Corral Pablo, Arrupe Matías, Augusto Lavalle Cobo, Gimenez Sergio, Renna Nicolás Federico","doi":"10.1007/s11892-024-01543-5","DOIUrl":null,"url":null,"abstract":"Purpose of review: The objective of this manuscript is to review and describe the relationship between Lp(a) and diabetes, exploring both their association and synergy as cardiovascular risk factors, while also describing the current evidence regarding the potential connection between low levels of Lp(a) and the presence of diabetes.Recent findings: Epidemiological studies suggest a potential relationship between low to very low levels of Lp(a) and diabetes. Lipoprotein(a), or Lp(a), is an intriguing lipoprotein of genetic origin, yet its biological function remains unknown. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular atherosclerosis, and coexisting diabetes status confers an even higher risk. On the other hand, epidemiological and genetic studies have paradoxically suggested a potential relationship between low to very low levels of Lp(a) and diabetes. While new pharmacological strategies are being developed to reduce Lp(a) levels, the dual aspects of this lipoprotein's behavior need to be elucidated in the near future.","PeriodicalId":10898,"journal":{"name":"Current Diabetes Reports","volume":" ","pages":"167-172"},"PeriodicalIF":5.2000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Diabetes Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11892-024-01543-5","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The objective of this manuscript is to review and describe the relationship between Lp(a) and diabetes, exploring both their association and synergy as cardiovascular risk factors, while also describing the current evidence regarding the potential connection between low levels of Lp(a) and the presence of diabetes.

Recent findings: Epidemiological studies suggest a potential relationship between low to very low levels of Lp(a) and diabetes. Lipoprotein(a), or Lp(a), is an intriguing lipoprotein of genetic origin, yet its biological function remains unknown. Elevated levels of Lp(a) are associated with an increased risk of cardiovascular atherosclerosis, and coexisting diabetes status confers an even higher risk. On the other hand, epidemiological and genetic studies have paradoxically suggested a potential relationship between low to very low levels of Lp(a) and diabetes. While new pharmacological strategies are being developed to reduce Lp(a) levels, the dual aspects of this lipoprotein's behavior need to be elucidated in the near future.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索糖尿病与脂蛋白（a）之间的相互作用：对心血管风险的影响。

综述目的：本手稿旨在回顾和描述脂蛋白（a）与糖尿病之间的关系，探讨两者作为心血管风险因素的关联性和协同作用，同时还描述了有关低水平脂蛋白（a）与糖尿病之间潜在联系的现有证据：流行病学研究表明，低水平或极低水平的脂蛋白（a）与糖尿病之间存在潜在的关系。脂蛋白（a）（或 Lp（a））是一种起源于遗传的有趣的脂蛋白，但其生物功能仍然未知。脂蛋白（a）水平升高与心血管动脉粥样硬化的风险增加有关，同时患有糖尿病的风险更高。另一方面，流行病学和遗传学研究却显示，低水平或极低水平的脂蛋白（a）与糖尿病之间存在潜在的关系。虽然目前正在开发降低脂蛋白（a）水平的新药物策略，但在不久的将来，这种脂蛋白行为的双重性还需要进一步阐明。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Diabetes Reports 医学 -

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The goal of this journal is to publish cutting-edge reviews on subjects pertinent to all aspects of diabetes epidemiology, pathophysiology, and management. We aim to provide incisive, insightful, and balanced contributions from leading experts in each relevant domain that will be of immediate interest to a wide readership of clinicians, basic scientists, and translational investigators. We accomplish this aim by appointing major authorities to serve as Section Editors in key subject areas across the discipline. Section Editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year on their topics, in a crisp and readable format. We also provide commentaries from well-known figures in the field, and an Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research.